Literature DB >> 17127330

Ubiquitin-like protein modifications in prostate and breast cancer.

Fangting Wu1, Yin-Yuan Mo.   

Abstract

Post-translational modifications by ubiquitin-like proteins have been implicated in the regulation of diverse cellular processes, including nuclear transport, transcription regulation, stress response and DNA repair. Ubiquitination is well characterized for its roles in regulating these cellular processes. As a newly identified member of ubiquitin-like proteins, the small ubiquitin-like modifier (SUMO) has received a great deal of attention for its functions distinct from ubiquitin. In particular, alterations of SUMO conjugation or sumoylation have been implicated in several human diseases, including cancer. Although little is known about the underlying mechanism of sumoylation-associated tumorigenesis, the modulation of nuclear receptor (NR)-mediated signaling pathways is likely to play a role in this aspect. NRs are a family of ligand dependent transcription factors which control cell growth and differentiation in many cell types, as well as during the development of cancer. In this review, we will discuss some basic aspects of sumoylation and how sumoylation modulates the NR-mediated gene expression, focusing on androgen receptor (AR) and estrogen receptor (ER), a key player in progression of prostate or breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17127330     DOI: 10.2741/2094

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  9 in total

Review 1.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

2.  Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction.

Authors:  Eun Young Kim; Li Chen; Yanlin Ma; Wei Yu; Jiang Chang; Ivan P Moskowitz; Jun Wang
Journal:  J Mol Cell Cardiol       Date:  2011-12-01       Impact factor: 5.000

Review 3.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

4.  Androgen receptor abnormalities in castration-recurrent prostate cancer.

Authors:  Lucas P Nacusi; Donald J Tindall
Journal:  Expert Rev Endocrinol Metab       Date:  2009-09-01

Review 5.  Nuclear protein isoforms: implications for cancer diagnosis and therapy.

Authors:  Fei Shen; Kashif Z Kirmani; Zhimin Xiao; Benjamin H Thirlby; Robert J Hickey; Linda H Malkas
Journal:  J Cell Biochem       Date:  2011-03       Impact factor: 4.429

Review 6.  Ubiquitin proteolytic system: focus on SUMO.

Authors:  Van G Wilson; Phillip R Heaton
Journal:  Expert Rev Proteomics       Date:  2008-02       Impact factor: 3.940

7.  Detection of proteins sumoylated in vivo and in vitro.

Authors:  Kevin D Sarge; Ok-Kyong Park-Sarge
Journal:  Methods Mol Biol       Date:  2009

8.  Inhibition of β-catenin signaling by nongenomic action of orphan nuclear receptor Nur77.

Authors:  Z Sun; X Cao; M-M Jiang; Y Qiu; H Zhou; L Chen; B Qin; H Wu; F Jiang; J Chen; J Liu; Y Dai; H-F Chen; Q-Y Hu; Z Wu; J-Z Zeng; X-S Yao; X-K Zhang
Journal:  Oncogene       Date:  2011-10-10       Impact factor: 9.867

9.  Network analysis of ChIP-Seq data reveals key genes in prostate cancer.

Authors:  Yu Zhang; Zhen Huang; Zhiqiang Zhu; Jianwei Liu; Xin Zheng; Yuhai Zhang
Journal:  Eur J Med Res       Date:  2014-09-03       Impact factor: 2.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.